233 related articles for article (PubMed ID: 24657936)
1. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
Marvaso G; Barone A; Amodio N; Raimondi L; Agosti V; Altomare E; Scotti V; Lombardi A; Bianco R; Bianco C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2014 Jun; 15(6):797-805. PubMed ID: 24657936
[TBL] [Abstract][Full Text] [Related]
2. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
3. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
4. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
5. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
6. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Tonelli F; Lim KG; Loveridge C; Long J; Pitson SM; Tigyi G; Bittman R; Pyne S; Pyne NJ
Cell Signal; 2010 Oct; 22(10):1536-42. PubMed ID: 20570726
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Omar HA; Chou CC; Berman-Booty LD; Ma Y; Hung JH; Wang D; Kogure T; Patel T; Terracciano L; Muthusamy N; Byrd JC; Kulp SK; Chen CS
Hepatology; 2011 Jun; 53(6):1943-58. PubMed ID: 21391227
[TBL] [Abstract][Full Text] [Related]
8. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Li MH; Hla T; Ferrer F
Pediatr Blood Cancer; 2013 Sep; 60(9):1418-23. PubMed ID: 23704073
[TBL] [Abstract][Full Text] [Related]
9. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy.
Zhang N; Qi Y; Wadham C; Wang L; Warren A; Di W; Xia P
Autophagy; 2010 Nov; 6(8):1157-67. PubMed ID: 20935520
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
12. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.
Zheng T; Meng X; Wang J; Chen X; Yin D; Liang Y; Song X; Pan S; Jiang H; Liu L
J Cell Biochem; 2010 Sep; 111(1):218-28. PubMed ID: 20506484
[TBL] [Abstract][Full Text] [Related]
13. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.
Potteck H; Nieuwenhuis B; Lüth A; van der Giet M; Kleuser B
Cell Physiol Biochem; 2010; 26(1):67-78. PubMed ID: 20502006
[TBL] [Abstract][Full Text] [Related]
17. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.
Lim KG; Sun C; Bittman R; Pyne NJ; Pyne S
Cell Signal; 2011 Oct; 23(10):1590-5. PubMed ID: 21620961
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells.
Long JS; Fujiwara Y; Edwards J; Tannahill CL; Tigyi G; Pyne S; Pyne NJ
J Biol Chem; 2010 Nov; 285(46):35957-66. PubMed ID: 20837468
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Paugh SW; Payne SG; Barbour SE; Milstien S; Spiegel S
FEBS Lett; 2003 Nov; 554(1-2):189-93. PubMed ID: 14596938
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]